Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide adequate glycemic control, weight reduction, low risk of hypoglycemia, and CV risk reduction. Their usage for type 2 DM (T2DM) is recommended mainly when hypoglycemia or weight gain should be considered, also, whenever initial therapy is failed. There are many recent updates in the treatment paradigm of T2DM. There are many types of GLP-1RAs, with a knowledge gap regarding switching between the different types. A Saudi task force gathered to develop an explicit, evidence-based consensus for switching between GLP-1RAs, when, why, and how? This article contains the expert panel’s recommendations as a contribution to complement the knowledge gap in this area from the national perspective. As an alternative to intensifying therapy, switching from one GLP-1RA to another has various advantages. Improvements in glycemic control, weight loss, adherence, and medications with established cardiovascular benefits are among them. Also, switching needs to be individualized upon many discussed factors like the dose of the previous GLP1-RA and gastrointestinal adverse effects. Discussion with patients about the why and how to switch is critical.
KeywordsGlucagon-Like Peptide-1 Receptor AgonistsSwitchingType 2 DMGlycemic Control
International Diabetes Federation (2017) IDF Diabetes Atlas. 8th Edition, International Diabetes Federation, Brussels. http://www.diabetesatlas.org
Al Dawish, M.A., Robert, A.A., Braham, R., Al Hayek, A.A., Al Saeed, A., Ahmed, R.A., et al. (2016) Diabetes Mellitus in Saudi Arabia: A Review of the Recent Literature. Current Diabetes Reports, 12, 359-368. https://doi.org/10.2174/1573399811666150724095130
American Diabetes Association (2020) 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care, 43, S98-S110. https://doi.org/10.2337/dc20-S009
Davies, M.J., D’Alessio, D.A., Fradkin, J., et al. (2018) Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 41, 2669-2701. https://doi.org/10.2337/dci18-0033
Garber, A.J., Handelsman, Y., Grunberger, G., et al. (2020) Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm— 2020 Executive Summary. Endocrine Practice, 26, 107-139. https://doi.org/10.4158/CS-2019-0472
U.S. Food & Drug Administration (2009) Prescribing Information: BYETTA ® (Exenatide) Injection. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf
U.S. Food & Drug Administration (2016) Prescribing Information: ADLYXIN ® (Lixisenatide) Injection, for Subcutaneous Use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208471orig1s000lbl.pdf
U.S. Food & Drug Administration (2018) Prescribing Information: BYDUREON ® (Exenatide Extended-Release) for Injectable Suspension, for Subcutaneous Use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022200s026lbl.pdf
U.S. Food & Drug Administration (2020) Prescribing Information: OZEMPIC ® (Semaglutide) Injection, for Subcutaneous Use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf
U.S. Food & Drug Administration (2014) Prescribing Information: TANZEUM ® (Albiglutide) for Injection, for Subcutaneous Use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125431s000lbl.pdf
U.S. Food & Drug Administration (2020) Prescribing Information: TRULICITY ® (Dulaglutide) Injection, for Subcutaneous Use. https://www.accessdata.fda.gov/drugstfda_docs/label/2017/125469s007s008lbl.pdf
U.S. Food & Drug Administration (2017) Prescribing Information: VICTOZA ® (Liraglutide) Injection, for Subcutaneous Use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf
Htike, Z.Z., Zaccardi, F., Papamargaritis, D., Webb, D.R., Khunti, K. and Davies, M.J. (2017) Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Analysis. Diabetes, Obesity and Metabolism, 19, 524-536. https://doi.org/10.1111/dom.12849
Witkowski, M., Wilkinson, L., Webb, N., Weids, A., Glah, D. and Vrazic, H. (2018) A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetic Drugs. Diabetes Therapy, 9, 1149-1167. https://doi.org/10.1007/s13300-018-0424-2
Gentilella, R., Pechtner, V., Corcos, A. and Consoli, A. (2019) Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Treatment: Are They All the Same? Diabetes/Metabolism Research and Reviews, 35, e3070. https://doi.org/10.1002/dmrr.3070
Hughes, S. and Neumiller, J.J. (2020) Oral Semaglutide. Clinical Diabetes, 38, 109-111. https://doi.org/10.2337/cd19-0079
Cosentino, F., Grant, P.J., Aboyans, V., et al. (2020) 2019 ESC Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases Developed in Collaboration with the EASD. European Heart Journal, 41, 255-323. https://doi.org/10.1093/eurheartj/ehz486
Jain, A.B., Ali, A., Gorgojo Martínez, J.J., et al. (2021) Switching between GLP-1 Receptor Agonists in Clinical Practice: Expert Consensus and Practical Guidance. European Heart Journal, 75, e13731. https://doi.org/10.1111/ijcp.13731
Almandoz, J.P., Lingvay, I., Morales, J. and Campos, C. (2020) Switching between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. Clinical Diabetes, 38, 390-402. https://doi.org/10.2337/cd19-0100
Buse, J.B., Nauck, M., Forst, T., et al. (2013) Exenatide Once Weekly versus Liraglutide Once Daily in Patients with Type 2 Diabetes (DURATION-6): A Randomised, Open-Label Study. The Lancet, 381, 117-124. https://doi.org/10.1016/S0140-6736(12)61267-7
Pratley, R.E., Nauck, M.A., Barnett, A.H., et al. (2014) Once-Weekly Albiglutide versus Once-Daily Liraglutide in Patients with Type 2 Diabetes Inadequately Controlled on Oral Drugs (HARMONY 7): A Randomised, Open-Label, Multicentre, Non-Inferiority Phase 3 Study. The Lancet Diabetes & Endocrinology, 2, 289-297. https://doi.org/10.1016/S2213-8587(13)70214-6
Nauck, M., Rizzo, M., Johnson, A., Bosch-Traberg, H., Madsen, J. and Cariou, B. (2016) Once-Daily Liraglutide versus Lixisenatide as Add-On to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. Diabetes Care, 39, 1501-1509. https://doi.org/10.2337/dc15-2479
Dungan, K.M., Povedano, S.T., Forst, T., et al. (2014) Once-Weekly Dulaglutide versus Once-Daily Liraglutide in Metformin-Treated Patients with Type 2 Diabetes (AWARD-6): A Randomised, Open-Label, Phase 3, Non-Inferiority Trial. The Lancet, 384, 1349-1357. https://doi.org/10.1016/S0140-6736(14)60976-4
Feher, M., Vega-Hernandez, G., Mocevic, E., et al. (2017) Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from the Health Improvement Network (THIN) Database in the United Kingdom. Diabetes Therapy, 8, 417-431. https://doi.org/10.1007/s13300-017-0241-z
Ahmann, A.J., Capehorn, M., Charpentier, G., et al. (2018) Efficacy and Safety of Once-Weekly Semaglutide versus Exenatide ER in Subjects with Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care, 41, 258-266. https://doi.org/10.2337/dc17-0417
Pratley, R.E., Aroda, V.R., Lingvay, I., et al. (2018) Semaglutide versus Dulaglutide Once Weekly in Patients with Type 2 Diabetes (SUSTAIN 7): A Randomised, Open-Label, Phase 3b Trial. The Lancet Diabetes & Endocrinology, 6, 275-286. https://doi.org/10.1016/S2213-8587(18)30024-X
Capehorn, M.S., Catarig, A.M., Furberg, J.K., et al. (2020) Efficacy and Safety of Once-Weekly Semaglutide 1.0 mg vs Once-Daily Liraglutide 1.2 mg as Add-On to 1-3 Oral Antidiabetic Drugs in Subjects with Type 2 Diabetes (SUSTAIN 10). Diabetes & Metabolism, 46, 100-109. https://doi.org/10.1016/j.diabet.2019.101117
Buse, J.B., Drucker, D.J., Taylor, K.L., et al. (2010) DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss over 52 Weeks. Diabetes Care, 33, 1255-1261. https://doi.org/10.2337/dc09-1914
Buse, J.B., Sesti, G., Schmidt, W.E., et al. (2010) Switching to Once-Daily Liraglutide from Twice-Daily Exenatide Further Improves Glycemic Control in Patients with Type 2 Diabetes Using Oral Agents. Diabetes Care, 33, 1300-1303. https://doi.org/10.2337/dc09-2260
Gorgojo-Martínez, J.J., Gargallo-Fernandez, M.A., Brito-Sanfiel, M. and Lisbona-Catalan, A. (2018) Real-World Clinical Outcomes and Predictors of Glycaemic and Weight Response to Exenatide Once Weekly in Patients with Type 2 Diabetes: The CIBELES Project. European Heart Journal, 72, e13055. https://doi.org/10.1111/ijcp.13055
Visaria, J., Dang-Tan, T., Petraro, P.V., Nepal, B.K. and Willey, V. (2019) Real-World Effectiveness of Semaglutide in Early Users from a U.S. Commercially Insured (CI) and Medicare Advantage (MA) Population. Diabetes, 68, 1006-P. https://doi.org/10.2337/db19-1006-P
Jain, A., Kanters, S., Khurana, R., Kissock, J., Severin, N. and Stafford, S. (2021) Real World Efficacy Analysis of Switch from Liraglutide or Dulaglutide to Semaglutide in Type 2 Diabetes Mellitus: REALiSe-DM Study. Diabetes Therapy, 12, 527-536. https://doi.org/10.1007/s13300-020-00984-x
Watanabe, Y., Saisho, Y., Inaishi, J., et al. (2020) Efficacy and Safety of Once Weekly Exenatide after Switching from Twice-Daily Exenatide in Patients with Type 2 Diabetes. Journal of Diabetes Investigation, 11, 382-388. https://doi.org/10.1111/jdi.13146
Goncalves, E. and Bell, D.S. (2019) Efficacy of Semaglutide versus Liraglutide in Clinical Practice. Diabetes & Metabolism, 46, 515-517. https://doi.org/10.1016/j.diabet.2019.10.001
Overgaard, R.V., Lindberg, S.Ø. and Thielke, D. (2019) Impact on HbA1c and Body Weight of Switching from Other GLP-1 Receptor Agonists to Semaglutide: A Model-Based Approach. Diabetes, Obesity and Metabolism, 21, 43-51. https://doi.org/10.1111/dom.13479
Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 375, 311-322. https://doi.org/10.1056/NEJMoa1603827
Gerstein, H.C., Colhoun, H.M., Dagenais, G.R., et al. (2019) Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial. The Lancet, 394, 121-130. https://doi.org/10.1016/S0140-6736(19)31149-3
Marso, S.P., Bain, S.C., Consoli, A., et al. (2016) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England Journal of Medicine, 375, 1834-1844. https://doi.org/10.1056/NEJMoa1607141
Pfeffer, M.A., Claggett, B., Diaz, R., et al. (2015) Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. The New England Journal of Medicine, 373, 2247-2257. https://doi.org/10.1056/NEJMoa1509225
Holman, R.R., Bethel, M.A., Mentz, R.J., et al. (2017) Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 377, 1228-1239. https://doi.org/10.1056/NEJMoa1612917
Fineman, M.S., Mace, K.F., Diamant, M., et al. (2012) Clinical Relevance of Anti-Exenatide Antibodies: Safety, Efficacy and Cross-Reactivity with Long-Term Treatment. Diabetes, Obesity and Metabolism, 14, 546-554. https://doi.org/10.1111/j.1463-1326.2012.01561.x
Bettge, K., Kahle, M., Abd El Aziz, M.S., Meier, J.J. and Nauck, M.A. (2017) Occurrence of Nausea, Vomiting and Diarrhoea Reported as Adverse Events in Clinical Trials Studying Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Analysis of Published Clinical Trials. Diabetes, Obesity and Metabolism, 19, 336-347. https://doi.org/10.1111/dom.12824
Nauck, M.A. and Meier, J.J. (2019) Management of Endocrine Disease: Are All GLP-1 Agonists Equal in the Treatment of Type 2 Diabetes? European Journal of Endocrinology, 181, R211-R234. https://doi.org/10.1530/EJE-19-0566
Bain, S.C. and McKenna, J. (2010) Clinical Experience with Liraglutide. International Journal of Clinical Practice. Supplement, 167, 44-48. https://doi.org/10.1111/j.1742-1241.2010.02494.x
Lin, L.K., Sun, Y., Heng, B.H., Chew, D.E.K. and Chong, P.N. (2017) Medication Adherence and Glycemic Control among Newly Diagnosed Diabetes Patients. BMJ Open Diabetes Research & Care, 5, e000429. https://doi.org/10.1136/bmjdrc-2017-000429
Aikens, J.E. and Piette, J.D. (2013) Longitudinal Association between Medication Adherence and Glycaemic Control in Type 2 Diabetes. Diabetic Medicine, 30, 338-344. https://doi.org/10.1111/dme.12046
Hamersky, C.M., Fridman, M., Gamble, C.L. and Iyer, N.N. (2019) Injectable Antihyperglycemics: A Systematic Review and Critical Analysis of the Literature on Adherence, Persistence, and Health Outcomes. Diabetes Therapy, 10, 865-890. https://doi.org/10.1007/s13300-019-0617-3
Coleman, C.I., Limone, B., Sobieraj, D.M., et al. (2012) Dosing Frequency and Medication Adherence in Chronic Disease. Journal of Managed Care & Specialty Pharmacy, 18, 527-539. https://doi.org/10.18553/jmcp.2012.18.7.527
Giorgino, F., Penfornis, A., Pechtner, V., Gentilella, R. and Corcos, A. (2018) Adherence to Antihyperglycemic Medications and Glucagon-Like Peptide 1-Receptor Agonists in Type 2 Diabetes: Clinical Consequences and Strategies for Improvement. Patient Preference and Adherence, 12, 707-719. https://doi.org/10.2147/PPA.S151736
Kruk, M.E. and Schwalbe, N. (2006) The Relation between Intermittent Dosing and Adherence: Preliminary Insights. Clinical Therapeutics, 28, 1989-1995. https://doi.org/10.1016/j.clinthera.2006.12.011
Qiao, Q., Ouwens, M.J., Grandy, S., Johnsson, K. and Kostev, K. (2016) Adherence to GLP-1 Receptor Agonist Therapy Administered by Once-Daily or Once-Weekly Injection in Patients with Type 2 Diabetes in Germany. Diabetes, Metabolic Syndrome and Obesity, 9, 201-205. https://doi.org/10.2147/DMSO.S99732
Nguyen, H., Dufour, R. and Caldwell-Tarr, A. (2017) Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population. Advances in Therapy, 34, 658-673. https://doi.org/10.1007/s12325-016-0470-y
Alatorre, C., Fernández Landó, L., Yu, M., et al. (2017) Treatment Patterns in Patients with Type 2 Diabetes Mellitus Treated with Glucagon-Like Peptide-1 Receptor Agonists: Higher Adherence and Persistence with Dulaglutide Compared with Once-Weekly Exenatide and Liraglutide. Diabetes, Obesity and Metabolism, 19, 953-961. https://doi.org/10.1111/dom.12902
Mody, R., Huang, Q., Yu, M., et al. (2019) Adherence, Persistence, Glycaemic Control and Costs among Patients with Type 2 Diabetes Initiating Dulaglutide Compared with Liraglutide or Exenatide Once Weekly at 12-Month Follow-Up in a Real-World Setting in the United States. Diabetes, Obesity and Metabolism, 21, 920-929. https://doi.org/10.1111/dom.13603
Qin, L., Chen, S., Flood, E., et al. (2017) Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom. Diabetes Therapy, 8, 335-353. https://doi.org/10.1007/s13300-017-0237-8
Qin, L., Chen, S., Flood, E., et al. (2017) Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naive Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study. Diabetes Therapy, 8, 321-334. https://doi.org/10.1007/s13300-017-0230-2
Gelhorn, H.L., Poon, J.L., Davies, E.W., Paczkowski, R., Curtis, S.E. and Boye, K.S. (2015) Evaluating Preferences for Profiles of GLP-1 Receptor Agonists among Injection-Naive Type 2 Diabetes Patients in the UK. Patient Preference and Adherence, 9, 1611-1622. https://doi.org/10.2147/PPA.S90842
Polonsky, W.H., Fisher, L., Hessler, D., Bruhn, D. and Best, J.H. (2011) Patient Perspectives on Once-Weekly Medications for Diabetes. Diabetes, Obesity and Metabolism, 13, 144-149. https://doi.org/10.1111/j.1463-1326.2010.01327.x
Thieu, V.T., Robinson, S., Kennedy-Martin, T., Boye, K.S. and Garcia-Perez, L.E. (2019) Patient Preferences for Glucagon-Like Peptide 1 Receptor-Agonist Treatment Attributes. Patient Preference and Adherence, 13, 561-576. https://doi.org/10.2147/PPA.S187907
Amylin Pharmaceuticals Inc. and Eli Lilly and Company (2006) Byetta Pen User Manual. https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021773s005lbl.pdf
Matfin, G., Van Brunt, K., Zimmermann, A.G., Threlkeld, R. and Ignaut, D.A. (2015) Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients with Type 2 Diabetes. Journal of Diabetes Science and Technology, 9, 1071-1079. https://doi.org/10.1177/1932296815583059
European Medicines Agency (2019) Summary of Product Characteristics: OZEMPIC® (Semaglutide). Hyperlink. https://www.ema.europa.eu/en https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf
American Diabetes Association (2020) 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2020. Diabetes Care, 43, S135-S151. https://doi.org/10.2337/dc20-S011
Rodbard, H.W., Lingvay, I., Reed, J., et al. (2018) Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. The Journal of Clinical Endocrinology & Metabolism, 103, 2291-2301. https://doi.org/10.1210/jc.2018-00070